Pharmaceuticals, Biotechnology and Life Sciences
MILPITAS, Calif.–(BUSINESS WIRE)–ASC Therapeutics, A Division of Applied StemCell, Inc. (ASC), announced today that it has obtained an exclusive therapeutics…
The European Commission (EC) has given Shire’s ADYNOVI a green light as an extended half-life recombinant factor VIII (rFVIII) treatment…
Hemophilia A, also called factor VIII (FVIII) deficiency or classic hemophilia, is a genetic disorder caused by missing or defective factor VIII, a clotting protein. Although it is passed down from parents to children, about 1/3 of cases are caused by a spontaneous mutation, a change in a gene.
BioMarin Pharmaceutical’s treatment for hemophilia has been accepted for PRIME (Priority Medicines) scheme from the European Medicines Agency (EMA).